Archive for the ‘Commercialization’ Category

Can we use animals as living incubators for human tissue?

Author: Jovana Drinjakovic, 01/16/17

Markus Grompe certainly thinks so and is working hard to make it happen. A scientist and a pediatrician specializing in inborn liver diseases, Dr. Grompe has a plan for overcoming the shortage of organ donors—the key obstacle for patients for whom the liver transplant is the only hope. Based at the Oregon Health and Science…Read more

A credit card sized lab

Author: Hamideh Emrani, 12/29/16

Professor Aaron Wheeler earned his PhD from Stanford University and, after a two-year postdoc fellowship at UCLA, joined the faculty of Chemistry at the University of Toronto. He has won numerous awards and honours for his work in the field of microfluidics and is the associate editor of Lab on a Chip. Wheeler’s lab develops…Read more

Inaugural Medicine by Design Symposium – Engineering progress in regenerative medicine

Author: Nicole Forgione, 12/21/16

On November 28 local and international leaders of the regenerative medicine (RM) community gathered at the MaRS Centre in Toronto for the first ever Medicine by Design (MbD) Symposium. The event marked the first year of the MbD program at the University of Toronto (U of T). This initiative was established based on a $114…Read more

Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs

Author: Guest, 12/01/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Insights from CGTW16 – Part 2: scale-up challenges and closed systems

Author: Guest, 11/23/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Insights from CGTW16 – Part 1: Cell Manufacturing Best Practices

Author: Guest, 11/17/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Making connections – advancing regenerative medicine through partnerships

Author: Nicole Forgione, 11/08/16

A key driver for advancements in regenerative medicine is partnerships. In recognition of this, every year CCRM hosts a networking reception that brings together our partners for an evening of discussion and knowledge sharing. This year’s industry networking reception was focused on the theme of increasing partnerships between industry and academia. I had the privilege…Read more

Ending on a high note – Day 3 of TMM2016

Author: Camila Londono, 10/31/16

Though the last day of the Till and McCulloch Meetings was a short one, it was absolutely fantastic. The day began with a thought-provoking talk by Douglas Sipp, from the Riken Center for Developmental Biology, touching upon the many issues surrounding regulation of stem cell therapies. I think as scientists, we often tend to forget…Read more

Special op/ed: Canada can lead the world in regenerative medicine — but it won’t happen without strategic investment

Author: Michael May, 08/30/16

Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into clinical applications, commercial products and public policy, and Peter Zandstra is a professor in…Read more

Right Turn: Has cancer immunotherapy arrived?

Author: Stacey Johnson, 07/29/16

It was Science magazine’s 2013 breakthrough of the year and called a “turning point in cancer.” It even scored its own awareness month that year. Cancer immunotherapy – therapies that harness the power of a patient’s immune system to fight their disease – had officially arrived. Fast-forward three years and now companies are tripping over…Read more